Management of acute graft-versus-host disease in children

Pediatric Clinics of North America

Volumn 57, Issue 1, 2010, Pages 273-295

  Carpenter, Paul A ^a,b   MacMillan, Margaret L ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Acute GVHD; Children; Graft versus host disease; Management

Indexed keywords

ALEFACEPT; ALEMTUZUMAB; ANTIINFECTIVE AGENT; BASILIXIMAB; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; DENILEUKIN DIFTITOX; ETANERCEPT; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INOLIMOMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTREOTIDE; OKT 3; PENTOSTATIN; PLACEBO; PREDNISONE; PSORALEN; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VISILIZUMAB;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT VERSUS HOST DISEASE; AUTOIMMUNE DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CYTOPENIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG OVERDOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; INFECTION; LIVER DISEASE; LIVER TOXICITY; LOADING DRUG DOSE; LUNG DISEASE; LYMPHOCYTOPENIA; MOUTH DISEASE; MYELOABLATIVE CONDITIONING; OPPORTUNISTIC INFECTION; PATIENT CARE; PUVA; REVIEW; SKIN DISEASE; TREATMENT DURATION; TREATMENT RESPONSE;

ACUTE DISEASE; CHILD; GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME;

EID: 77951075744     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2009.11.007     Document Type: Review

References (78)

1. Morris E.S., Hill G.R. Advances in the understanding of acute graft-versus-host disease. Br J Haematol 2007, 137:3-19.
2. Beatty P.G., Hansen J.A., Longton G.M., et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991, 51:443-447.
3. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
4. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986, 314:729-735.
5. Beatty P.G., Clift R.A., Mickelson E.M., et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985, 313:765-771.
6. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
7. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109:3108-3114.
8. Kernan N.A. T-cell depletion for the prevention of graft-versus-host disease. Hematopoietic cell transplantation 1999, 186-196. Blackwell Science, Boston. 2nd edition. E.D. Thomas, K.G. Blume, S.J. Forman (Eds.).
9. Ruutu T., Eriksson B., Remes K., et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002, 100:1977-1983.
10. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
11. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
12. Martin P.J., Nelson B.J., Appelbaum F.R., et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1996, 88:824-830.
13. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
14. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997, 97:855-864.
15. Sale G.E. Pathology and recent pathogenetic studies in human graft-versus-host disease. Surv Synth Pathol Res 1984, 3:235-253.
16. Sale G.E., Shulman H.M., Gallucci B.B., et al. Young rete ridge keratinocytes are preferred targets in cutaneous graft-versus-host disease. Am J Pathol 1985, 118:278-287.
17. Furlong T., Leisenring W., Storb R., et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transplant 2002, 8:206-212.
18. McDonald G.B., Bouvier M., Hockenbery D.M., et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology 1998, 115:28-35.
19. Hockenbery D.M., Cruickshank S., Rodell T.C., et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007, 109:4557-4563.
20. McDonald G.B. Oral beclomethasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease following allogeneic hematopoietic cell transplantation [review]. Expert Opin Investig Drugs 2007, 16:1709-1724.
21. Iyer R.V., Hahn T., Roy H.N., et al. Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2005, 11:587-592.
22. Bertz H., Afting M., Kreisel W., et al. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant 1999, 24:1185-1189.
23. Levine A., Weizman Z., Broide E., et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003, 36:248-252.
24. Levine A., Kori M., Dinari G., et al. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial. Inflamm Bowel Dis 2009, 15:1055-1061.
25. van Lint M.T., Uderzo C., Locasciulli A., et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998, 92:2288-2293.
26. Vogelsang G.B., Hess A.D., Santos G.W. Acute graft-versus-host disease: clinical characteristics in the cyclosporine era. Medicine 1988, 67:163-174.
27. Cragg L., Blazar B.R., DeFor T., et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000, 6:441-447.
28. Lee S.J., Zahrieh D., Agura E., et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004, 104:1559-1564.
29. Levine J.E., Paczesny S., Mineishi S., et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008, 111:2470-2475.
30. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the blood and marrow transplant clinical trials network. Blood 2009, 114:511-517.
31. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990, 76:1464-1472.
32. Weisdorf D.J., Snover D.C., Haake R., et al. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 1990, 76:624-629.
33. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
34. Mielcarek M., Storer B.E., Boeckh M., et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009, 113:2888-2894.
35. Baehr P.H., Levine D.S., Bouvier M.E., et al. Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease. Transplantation 1995, 60:1231-1238.
36. van Lint M.T., Milone G., Leotta S., et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006, 107:4177-4181.
37. Antin J.H., Chen A.R., Couriel D.R., et al. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2004, 10:655-668.
38. Kebriaei P., Isola L., Bahceci E., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:804-811.
39. Ruutu T., Niederwieser D., Gratwohl A., et al. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT). Chronic leukaemia working party of the EBMT. Bone Marrow Transplant 1997, 19:759-764.
40. Ruutu T., Hermans J., van Biezen A., et al. How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998, 22:614-615.
41. Nichols W.G., Corey L., Gooley T., et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001, 97:867-874.
42. Hakki M., Riddell S.R., Storek J., et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003, 102:3060-3067.
43. Marr K.A., Carter R.A., Boeckh M., et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002, 100:4358-4366.
44. Fukuda T., Boeckh M., Carter R.A., et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003, 102:827-833.
45. Lee S.J., Vogelsang G., Flowers M.E.D. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9:215-233.
46. Weisdorf D., Haake R., Blazar B., et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990, 75:1024-1030.
47. Hings I.M., Severson R., Filipovich A.H., et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation 1994, 58:437-442.
48. Khoury H., Kashyap A., Adkins D.R., et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001, 27:1059-1064.
49. McCaul K.G., Nevill T.J., Barnett M.J., et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000, 9:367-374.
50. Przepiorka D., Kernan N.A., Ippoliti C., et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000, 95:83-89.
51. Ho V.T., Zahrieh D., Hochberg E., et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:1224-1226.
52. Couriel D.R., Saliba R.M., Giralt S., et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004, 10:178-185.
53. Carpenter P.A., Lowder J., Johnston L., et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2005, 11:465-471.
54. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant 2009, 44:453-455.
55. Remberger M., Aschan J., Barkholt L., et al. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin [review]. Clin Transplant 2001, 15:147-153.
56. MacMillan M.L., Weisdorf D.J., Davies S.M., et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002, 8:40-46.
57. Arai S.M. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002, 8:155-160.
58. Perales M.A., Ishill N., Lomazow W.A., et al. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant 2007, 40:481-486.
59. Rao K., Rao A., Karlsson H., et al. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease. J Pediatr Hematol Oncol 2009, 31:456-461.
60. Miano M., Cuzzubbo D., Terranova P., et al. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience. Bone Marrow Transplant 2009, 43:423-427.
61. Patriarca F., Sperotto A., Damiani D., et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004, 89:1352-1359.
62. Sleight B.S., Chan K.W., Braun T.M., et al. Infliximab for GVHD therapy in children. Bone Marrow Transplant 2007, 40:473-480.
63. Busca A., Locatelli F., Marmont F., et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007, 82:45-52.
64. Greinix H.T., Volc-Platzer B., Kalhs P., et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000, 96:2426-2431.
65. Greinix H.T., Knobler R.M., Worel N., et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006, 91:405-408.
66. Messina C., Locatelli F., Lanino E., et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003, 122:118-127.
67. Calore E., Calo A., Tridello G., et al. Extracorporeal photochemotherapy may improve outcome in children with acute GVHD. Bone Marrow Transplant 2008, 42:421-425.
68. Perfetti P., Carlier P., Strada P., et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 2008, 42:609-617.
69. Basara N., Blau W.I., Kiehl M.G., et al. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Transplant Proc 1998, 30:4087-4089.
70. Basara N., Kiehl M.G., Blau W., et al. Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplant Proc 2001, 33:2121-2123.
71. Nash R.A., Furlong T., Storb R., et al. Mycophenolate mofetil (MMF) as salvage treatment for graft-versus-host-disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT): safety analysis [abstract]. Blood 1997, 90(Suppl 1):105A. #459.
72. Benito A.I., Furlong T., Martin P.J., et al. Sirolimus (Rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001, 72:1924-1929.
73. Bolanos-Meade J., Jacobsohn D.A., Margolis J., et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005, 23:2661-2668.
74. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
75. Ringdén O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
76. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
77. Prasad V.K., Lucas K.G., Kleiner G.I., et al. Use of mesenchymal stem cells to treat pediatric patients with severe (grade III-IV) acute graft versus host disease refractory to steroid and other agents on a compassionate use basis [abstract]. Blood 2007, 118(Part 1):872A-873A. #2971.
78. Ippoliti C., Champlin R., Bugazia N., et al. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. J Clin Oncol 1997, 15:3350-3354.